Clinical trial NCT06474598: An Adaptive Design Study of MTX228
Official title: A Open Label, Parallel Group Phase IIA, Adaptive Design Study of MTX228 in Adult Subjects With Type 1 Diabetes and Preserved β-Cell Function
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Type 1 Diabetes Mellitus
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2024-06-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study.

The purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.

Detailed description: MTX228 was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, MTX228 has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as MTX228, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabetes.

MTX228 has not been testing in clinical studies in type 1 diabetes and the optimal dose to use is not clear from the clinical trial in type 2 diabetes, where lower doses (100 mg once or twice daily) were more effective than higher doses (200 mg once or twice daily). The purpose of this study is to compare the effect of different doses of MTX228 in order to determine the most effective dose to move forward in a subsequent phase 2b study.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of T1DM with onset before the age of 35 requiring continuous treatment with insulin within 1 year of diagnosis and the presence of positive T1DM autoantibody titer if diagnosed after age 35 (past or present
* HbA1c between 6.0 - 10.0 %.
* Willing to wear study-provided CGM and share CGM data via cloud.
* Diagnosis of T1DM ≥1year at time of screening.
* Fasting or random (post-prandial) C-peptide level ≥ 100 pmol/l (or 0.3 ng/mL) during screening or pre-screening. Pre-screening C-peptide levels may be obtained by the study team (subject to patient's written consent) up to 56 days before planned enrolment to reduce the number of screen failures.
* BMI ≤ 35 kg/m2
* eGFR \>45 ml/min/1.73m2
* Able and willing to comply with the study protocol for the duration of the study
* Written informed consent must be obtained before any study-related assessment is performed.

Exclusion Criteria:

* Diagnosis or history indicative of monogenic, Type 2 or post-pancreatectomy diabetes
* History of \>1 episode of severe (level 3) hypoglycemia in the prior 6 months
* Significant cardiovascular history defined as:

  1. History of myocardial infarction, coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accidents within six months prior to entry into the study
  2. Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV
  3. Uncontrolled hypertension defined as SBP \> 160 mmHg and/or DBP \> 100 mmHg
  4. Symptomatic postural hypotension
  5. Use of systemic corticosteroids (except physiologic replacement doses for adrenal insufficiency) or other medications that would influence insulin sensitivity
  6. Use of non-insulin antihyperglycemic agents within prior 30 days.
  7. History of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, or urological disorder including previous solid organ or cell transplant that would impact patient safety or data interpretation.
  8. History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years before screening (any history of treated cervical intraepithelial neoplasia is allowed)
  9. Known recreational substance use or psychiatric illness that, in the opinion of the Investigator, may impact the safety of the subject or objectives with scheduled visits
  10. A history of alcohol or drug abuse or drug addiction in the previous 12 months
  11. A positive pregnancy blood test for women of childbearing age or breast-feeding women 12 Are unwilling to use an "effective" method of contraception during the course of the study. Sexually active male patients, who could have children, are required to use a condom or abstained from intercourse, and refrain from sperm donation for the purposes of conception. Females have to be surgically sterile (via hysterectomy or bilateral tubal ligation) or post-menopausal or using a medically acceptable barrier method of contraception (i.e. IUD, barrier methods with spermicide or abstinence).

Primary outcomes:
measure: Change in AUC C-peptide
timeFrame: Days 0 and 84
measure: Dose selection for phase IIb study
timeFrame: Days 0 and 84
Secondary outcomes:
measure: Lowered or increased total daily insulin dose
timeFrame: Days 84 and 168
measure: To assess the time spent in a plasma glucose range of 3.9-10.0 mol/L
timeFrame: Days 84 and 168
measure: Time spent in high range (10.1-13.9 mmol/L) and very high range (>13.9) based upon CGM in the last two weeks of the main treatment period and separately of the extended treatment
timeFrame: Days 84 and 168
measure: Change in HbA1c
timeFrame: Days 84 and 168
measure: Change in fasting plasma glucose (FPG)
timeFrame: Days 84 and 168
measure: The number of episodes of level 2 and 3 hypoglycemia in study participants
timeFrame: Days 84 and 168
Other outcomes:
measure: Changes in AUC C-peptide between days 0 and 168, and between Days 84 and 168 in those completing the optional extension study.
timeFrame: days 0 and 168, and between Days 84 and 168
measure: •Changes in secondary end-points between days 0 and 168, and between Days 84 and 168 (in subjects completing the extension study)
timeFrame: days 0 and 168, and between Days 84 and 168
measure: •Stratified analysis by baseline C-peptide level, diabetes duration, age of diabetes onset, HbA1c
timeFrame: days 0 and 168, and between Days 84 and 168
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
References: